HPV18 E6 Antibody (BF7): sc-53328
- HPV18 E6 Antibody (BF7) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against gel-purified HPV18 E6-β-galactosidase fusion protein
- recommended for detection of HPV by WB and IF
- See HPV16 E6/18 E6 (C1P5): sc-460 for HPV18 E6 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for HPV18 E6 Antibody (BF7) for WB applications. These reagents are now offered in bundles with HPV18 E6 Antibody (BF7) (see ordering information below).
QUICK LINKS
SEE ALSO...
HPV18 E6 Antibody (BF7) is a mouse monoclonal IgG1 antibody that detects HPV18 E6 in HPV by applications such as western blotting (WB) and immunofluorescence (IF). HPV18 E6 plays a crucial role in the pathogenesis of cervical cancer by binding to and promoting the degradation of the p53 tumor suppressor protein, which is essential for regulating the cell cycle and preventing genomic instability. The inactivation of p53 by HPV18 E6 leads to uncontrolled cell proliferation and contributes to the malignant transformation of infected cells, making HPV18 E6 a significant target for cancer research and diagnostics. Anti-HPV18 E6 antibody (BF7) is particularly valuable for detecting HPV in cervical smears and biopsies, as well as for analyzing E6 expression in cell transformation studies, thereby aiding in the understanding of HPV-related oncogenesis and the development of potential therapeutic strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HPV18 E6 Antibody (BF7) References:
- Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 transcription through alteration of chromatin histone deacetylation. | Chakraborty, S., et al. 2014. J Biol Chem. 289: 29074-85. PMID: 25157104
- Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model. | Ma, Y., et al. 2017. Vaccine. 35: 3850-3858. PMID: 28599791
- Expression of the HPV18/E6 oncoprotein induces DNA damage. | Cortés Gutiérrez, EI., et al. 2017. Eur J Histochem. 61: 2773. PMID: 28735519
- Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer. | Ling, K., et al. 2020. Hum Gene Ther. 31: 297-308. PMID: 31989837
- IL-6/STAT3 mediates the HPV18 E6/E7 stimulated upregulation of MALAT1 gene in cervical cancer HeLa cells. | Hao, Y., et al. 2020. Virus Res. 281: 197907. PMID: 32113834
- Antiproliferative effects of AAV-delivered CRISPR/Cas9-based degradation of the HPV18-E6 gene in HeLa cells. | Noroozi, Z., et al. 2022. Sci Rep. 12: 2224. PMID: 35140292
- Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice. | Peng, S., et al. 2022. J Biomed Sci. 29: 80. PMID: 36224625
- HPV18 E6 inhibits α-ketoglutarate-induced pyroptosis of esophageal squamous cell carcinoma cells via the P53/MDH1/ROS/GSDMC pathway. | Tang, D., et al. 2023. FEBS Open Bio. 13: 1522-1535. PMID: 37402485
- HPV18 E6/E7 activates Ca2+ influx to promote the malignant progression of cervical cancer by inhibiting Ca2+ binding protein 1 expression. | Kang, C., et al. 2024. Biotechnol Appl Biochem.. PMID: 39113388
- The Expressions of p16, HPV16-L1 and HPV18-E6 in Salivary Gland Tumours. | Zakir, NNM., et al. 2024. Indian J Otolaryngol Head Neck Surg. 76: 5470-5477. PMID: 39559137
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HPV18 E6 Antibody (BF7) | sc-53328 | 200 µg/ml | $322.00 | |||
HPV18 E6 Antibody (BF7): m-IgG Fc BP-HRP Bundle | sc-536935 | 200 µg Ab; 10 µg BP | $361.00 | |||
HPV18 E6 Antibody (BF7): m-IgGκ BP-HRP Bundle | sc-534111 | 200 µg Ab; 40 µg BP | $361.00 | |||
HPV18 E6 Antibody (BF7): m-IgG1 BP-HRP Bundle | sc-544908 | 200 µg Ab; 20 µg BP | $361.00 |